Loading
Hangzhou Hanx Biopharmaceuticals
Hangzhou Hanx Biopharmaceuticals is a China-based biotechnology company running 2 late-stage cancer trials of HX009 in glioma & glioblastoma, biliary tract cancer and melanoma.
Also called: Hangzhou Hanx Biopharmaceuticals, Ltd.
Overview
Hangzhou Hanx Biopharmaceuticals, based in Wuhan, China, is a biotechnology company. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing HX009 in glioma & glioblastoma, biliary tract cancer and melanoma. The largest, NCT06708663 (HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours), plans to enrol 124 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Connected
6Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
hanxbio.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/
ProvenanceLast edited 2026-09-18 · Jude Gomila · Merge worktree-agent-a92b346da6e5b3a8a (orphan trials con… · diff · file
Sourced, not expert-reviewed